FBLG
EquityFibroBiologics, Inc.
Health Care · Biotechnology
$0.33
+0.33 (+0.00%)
Open
N/A
Day Range
$0.30 - $0.33
52W Range
$0.22 - $1.53
Volume
1M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
FBLG: Ready to Transition to Clinical-Stage Company
FibroBiologics to Present at the BIO Investment & Growth Summit
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
About FibroBiologics, Inc.
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.
fibrobiologics.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for FBLG
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for FBLG.